Clinical Trials for Pancreas Cancer

An Open-label Phase 1 Study to Evaluate the Safety and Tolerability of SX-682 in Combination With Nivolumab as a Maintenance Therapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic pancreatic ductal adenocarcinoma that has not progressed after at least 16 weeks of first-line chemotherapy receive maintenance oral SX-682, an investigational CXCR1/2 inhibitor, plus nivolumab, a PD-1–blocking antibody. Patients must have ECOG performance status 0–1 and be able to undergo tumor biopsies.

ClinicalTrials.gov ID: NCT04477343

Ulixertinib (BVD-523) in Combination With Palbociclib in Patients With Advanced Solid Tumors With Expansion Cohort in Previously Treated Metastatic Pancreatic Cancer and Metastatic RAS-mutant and NF1-mutant (no BRAFV600 Mutations) Melanoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with refractory advanced solid tumors receive oral ulixertinib, an ERK1/2 inhibitor, plus palbociclib, a CDK4/6 inhibitor. Expansion cohorts include previously treated metastatic pancreatic cancer and unresectable or metastatic RAS- or NF1-mutant melanoma without a BRAF V600 mutation; the pancreatic and all-solid-tumor cohorts are closed to enrollment.

ClinicalTrials.gov ID: NCT03454035

A Study to Assess the Safety of Intratumoral Diffusing Alpha Radiation Emitters With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma (ECOG 0–2) with a ≤5 cm lesion amenable to implantation receive standard mFOLFIRINOX plus intratumoral Alpha DaRT, an Ra-224–based brachytherapy delivering short-range alpha particles for local cytotoxicity. Key aims include safety, pain control, and, in locally advanced cases, potential conversion to resectability.

ClinicalTrials.gov ID: NCT06698458

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (G1–2), SSTR-positive gastroenteropancreatic NETs with hepatic metastases undergo cytoreductive surgery followed within 90 days by standard PRRT with lutetium Lu 177 dotatate (a radiolabeled somatostatin analog delivering beta radiation to SSTR-expressing cells) every 8 weeks for up to 4 cycles. Excludes G3 disease, inoperable tumors >3 cm, prior PRRT, and uncontrolled comorbidities; outcomes include PFS, ORR by RECIST, safety, and SSTR-PET changes.

ClinicalTrials.gov ID: NCT06016855

Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with histologically confirmed pancreatic ductal adenocarcinoma and nominal oligometastatic disease (1–5 lesions), ECOG 0–2, eligible for definitive local therapy to all sites, are randomized to standard systemic therapy alone versus systemic therapy plus comprehensive metastasis-directed therapy (e.g., SBRT/external-beam RT, surgery, ablation, or embolization to all known sites, including the primary). Suitable for patients without malignant effusions/peritoneal carcinomatosis and with recent imaging confirming oligometastatic status; prior induction to oligometastatic state allowed if sustained ≥6 months.

ClinicalTrials.gov ID: NCT06593431

A Phase II Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreas Cancer With FGFR2 Gene Fusions or Other FGFR Genetic Alterations

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with advanced/metastatic pancreatic cancer harboring FGFR alterations receive oral pemigatinib (FGFR1–3 tyrosine kinase inhibitor) in 21‑day cycles; Cohort 1 requires FGFR2 fusion/translocation and KRAS-wild type, while Cohort 2 includes other activating FGFR1/2/3/4 alterations (KRAS co-mutations allowed), all after progression/intolerance to standard therapy and no prior FGFR inhibitor. Single-arm telemedicine study assessing response, PFS, and safety, with attention to class‑typical toxicities (e.g., hyperphosphatemia, ocular events).

ClinicalTrials.gov ID: NCT06906562

A Phase I Study of Fulvestrant in Combination With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with well-differentiated (G1–2), SSTR-positive pancreatic NETs that are unresectable/metastatic and have progressed after ≥1 prior systemic therapy (no prior PRRT or fulvestrant) receive 177Lu-DOTATATE plus fulvestrant. Fulvestrant, a selective estrogen receptor degrader with potential radiosensitizing effects, is combined with standard PRRT to assess safety and preliminary efficacy.

ClinicalTrials.gov ID: NCT06663072

A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with CLDN18.2-positive, locally advanced unresectable or metastatic gastric/GEJ or pancreatic adenocarcinoma and ECOG 0–1 receive ASP2138 alone or in disease- and treatment-line–specific combinations with pembrolizumab plus mFOLFOX6, ramucirumab plus paclitaxel, or mFOLFIRINOX. ASP2138 is an investigational bispecific antibody that binds CLDN18.2 on tumor cells and CD3 on T cells to recruit T-cell activity.

ClinicalTrials.gov ID: NCT05365581

A Phase I Clinical Trial of CA-4948 in Combination With Gemcitabine and Nab-Paclitaxel in Metastatic or Unresectable Pancreatic Ductal Carcinoma

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with metastatic or unresectable pancreatic ductal adenocarcinoma that progressed on or after fluorouracil-based therapy receive emavusertib, an investigational IRAK4/FLT3 inhibitor, plus gemcitabine and nab-paclitaxel. Prior gemcitabine/nab-paclitaxel for advanced disease is not permitted.

ClinicalTrials.gov ID: NCT05685602

A Phase 1 Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Patients with advanced or metastatic solid tumors after standard therapy, or without a suitable standard option, receive givastomig alone; dose-expansion patients must have CLDN18.2-positive tumors. A separate group of treatment-naïve patients with CLDN18.2-positive, unresectable or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma receives givastomig with nivolumab and chemotherapy; givastomig is a bispecific antibody that targets CLDN18.2 and provides 4-1BB–mediated T-cell costimulation.

ClinicalTrials.gov ID: NCT04900818